Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 34 of 36.
Apr 2009
28 Apr · Results
Standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 169852 lacs for year ending on 31-MAR-2009 against Rs. 174160 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 26591 lacs for the year ending on 31-MAR-2009 against Rs. 23620 lacs for the year ending on 31-MAR-2008.28 Apr · Results
Consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 286240 lacs for year ending on 31-MAR-2009 against Rs. 226600 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 30308 lacs for the year ending on 31-MAR-2009 against Rs. 25760 lacs for the year ending on 31-MAR-2008.28 Apr · Business
Press release dated April 28, 2009, titled "Zydus Cadila's Total Income up by whopping 26% in FY 09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 70255 lacs for quarter ending on 31-MAR-2009 against Rs. 54690 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 5800 lacs for the quarter ending on 31-MAR-2009 against Rs. 5200 lacs for the quarter ending on 31-MAR-2008.15 Apr · Board meeting
To consider amongst others audited financial results and for recommendation of dividend for the year ended March 31, 2009.15 Apr · Results
Company proposes to submit audited financial results for the entire financial year ended on March 31, 2009 instead of providing unaudited financial results for the quarter ended on March 31, 2009. In view of the above, the Company shall provide to the exchange audited financial results for the year ended March 31, 2009 within three months from March 31, 2009.2 Apr · Business
Press release dated April 02, 2009, titled "Zydus files IND application with the USFDA for 'ZYT1' a novel candidate to treat dyslipidemia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
31 Mar · Business
Company has received final approval from USFDA to market Topiramate Tablets in different strengths of 25 mg., 50 mg., 100 mg., and 200 mg. In this regard the Company has submitted a press release dated March 31, 2009, titled "Zydus receives final approval for Topiramate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Mar · Business
Company has signed new drug discovery and development agreement with Eli Lilly to discover and develop new Cardiovascular medicines. In this regard the Company has submitted a press release dated March 30, 2009, titled "Zydus Cadila announces research collaboration to discover and develop new cardiovascular medicines". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Press release dated March 04, 2009, titled "Zydus Research Centre Receives AAALAC Accreditation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
9 Feb · Allotment of shares/ others
The Committee of Board of Directors of Cadila Healthcare Limited ("the Company") held on 7th February 2009 have consented to the allotment of 100,885,305 (Ten Crores Eight Lacs Eighty Five Thousand Three Hundred and Five only) Equity Shares of Rs.5/- each fully paid-up (referred to as "New Equity Shares") to the shareholders of Zydus Hospitals and Medical Research Private Limited (ZHMRPL) whose names appeared in the Register of Members as on the Amalgamation Record Date i.e. 4th February 2009, in proportion to their holding in ZHMRPL. The New Equity Shares shall be subject to the Memorandum and Articles of Association of the Company and shall rank pari passu in all respects with and carry the same rights as the existing equity shares of the Company as mentioned in the Composite Scheme of Arrangement (Scheme). As per the Scheme 9,00,00,000 Equity Shares of the Company held by ZHMRPL will be cancelled
Jan 2009
27 Jan · Business
Press release dated January 27, 2009, titled "Zydus Cadila's Total Income up by 31% in Q3". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 73627 lacs for quarter ending on 31-DEC-2008 against Rs. 56140 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 6053 lacs for the quarter ending on 31-DEC-2008 against Rs. 5160 lacs for the quarter ending on 31-DEC-2007.27 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 36810 lacs for quarter ending on 31-DEC-2008 against Rs. 40630 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 7224 lacs for the quarter ending on 31-DEC-2008 against Rs. 6310 lacs for the quarter ending on 31-DEC-2007.12 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter ended on December 31, 2008.
Dec 2008
29 Dec · Results
Members of the Company have approved with requisite majority, through postal ballot process, the resolution for alteration of the Memorandum of Association of the Company as set out in the notice, the results of which was announced on December 29, 2008 by the Chairman. Further, the Special Resolution as mentioned in the Notice of Postal Ballot dated November 03, 2008 has been passed with requisite majority. The details of the results of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Dec · Updates
Zydus Pharmaceuticals USA, Inc, USA a Joint Venture Company, wherein Cadila Healthcare Limited was holding 70% stake through its Irish subsidiary Company, has bought back 30% issued shares held by the JV partners. In view of the buy back of shares, Zydus Pharmaceuticals USA, Inc has now become a 100% subsidiary of the Company.5 Dec · Corporate action
Cadila Healthcare Limited had informed the Exchange that the Hon'ble High Court of Gujarat at Ahmedabad, has approved the Composite Scheme of Arrangement between Cadila Healthcare Limited ("Cadila") and Carnation Nutra - Analogue Foods Limited "(Carnation)" and Zydus Hospitals and Medical Research Private Limited ("ZHMRPL") on October 23, 2008. At the meeting of the committee of Board of Directors held on December 05, 2008 fixed January 05, 2009 as the Record date for the purpose of the determination of members entitled to receive the Shares of Carnation Nutra- Analogue Foods Limited in the ratio of 4(four) equity shares of Rs.10/- each fully paid up for every 15(Fifteen) equity shares of Rs. 5 each fully paid-up held by them on the record date as consideration for Demerger of Consumer Products Division (CPD) of the Company into Carnation. A detailed note on the shcme shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Dec · Business
Hon'ble High Court of Gujarat at Ahmedabad has at the hearing held on October 23, 2008, approved the Composite Scheme of Arrangement between Carnation Nutra-Analogue Foods Limited ("Carnation") and Cadila Healthcare Limited ("Cadila") and Zydus Hospitals and Medical Research Private Limited ("ZHMRPL") and their respective shareholders and creditors ('Composite Scheme') for the transfer of the Consumer Products Division of Cadila into Carnation and amalgamation of ZHMRPL with Cadila.
Nov 2008
25 Nov · Meeting
In accordance with the provisions of Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution by Postal Ballot) Rules, 2001 following resolution is circulated for approval of members of the Company by way of postal ballot : Special Resolution pursuant to Section 17 of the Companies Act, 1956 read with Section 192A of the Companies Act, 1956 for incorporation of a new Clause in the Objects incidental or ancillary to the attainment of the main objects in the Memorandum of Association of the Company. The Company has appointed Mr. Dhirajlal D. Sanghavi, Practicing Company Secretary, as Scrutinizer for conducting the Postal Ballot process. The duly completed postal ballot forms should reach the Scrutinizer before the close of the working hours on or before December 20, 2008. The Scrutinizer will submit his report to the Chairman of the company after completion of the Scrutiny. The results of the voting by Postal Ballot will be announced through a press release by December 31, 2008. A copy of the notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Nov · Business
Press release dated November 11, 2008, titled "Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
22 Oct · Results
Standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 89985 lacs for half year ending on 30-SEP-2008 against Rs. 89970 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 15114 lacs for the half year ending on 30-SEP-2008 against Rs. 13770 lacs for the half year ending on 30-SEP-2007.22 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 47072 lacs for quarter ending on 30-SEP-2008 against Rs. 44740 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 9550 lacs for the quarter ending on 30-SEP-2008 against Rs. 7130 lacs for the quarter ending on 30-SEP-2007.22 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 73785 lacs for quarter ending on 30-SEP-2008 against Rs. 60970 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 9488 lacs for the quarter ending on 30-SEP-2008 against Rs. 8010 lacs for the quarter ending on 30-SEP-2007.22 Oct · Business
Press release dated October 22, 2008, titled "Zydus Cadila registers 33% increase in Operating Net Profit in Q2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 142358 lacs for half year ending on 30-SEP-2008 against Rs. 118190 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 18455 lacs for the half year ending on 30-SEP-2008 against Rs. 15400 lacs for the half year ending on 30-SEP-2007.20 Oct · Business
Press release dated October 20, 2008, titled "Zydus receives approval for Risperidone Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Oct · Business
Filing of the IND application for ZYT1-a novel lipid lowering molecule with the DCGI. Designed and developed at the Company's R&D Centre, ZYT1 is a novel, anti-dyslipidemic agent which may provide an alternative to statins or be an add-on to statin therapy. Further the Company has submitted a copy of press release dated October 16, 2008 "Zydus files IND application for 'ZYT1' a novel candidate to treat dyslipidemia"shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Business
"The World Health Organization has approved Lyssavac N - the Purified Duck Embroyo Rabies Vaccine (PDEV) manufactured by the Company, for purchase by various United Nation Agencies. With this, the Company has becomes the first Indian Pharma Company and the Second Pharma Company in the world, to receive the WHO accreditation (prequalification) for rabies vaccine". Further the Company has submitted a copy of press release dated October 14, 2008, titled "Zydus Cadila becomes the 1st Indian Pharma company to receive WHO accreditation for Rabies Vaccine". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Board meeting
To consider amongst others unaudited financial results for the quarter/half year ended on September 30, 2008.6 Oct · Notice
Further to the Composite Scheme of Arrangement being approved by the Equity Shareholders and Unsecured Creditors of Cadila Healthcare Limited ("the Company"), the Company had filed a company Petition with the Hon'ble High Court of Gujarat at Ahmedabad on September 22, 2008. Subsequently, the Hon'ble High Court, by an order made on September 23, 2008 has directed that the Petition is fixed for hearing and final disposal on October 20, 2008 and notice of the hearing of the Petition to be advertised in Newspapers at least, 10 days before the date of hearing so fixed. The notice of Petition was published in the newspapers on September 26, 2008. A copy of the notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
23 Sep · Business
Meeting of the Equity Shareholders and Unsecured Creditors of Cadila Healthcare Limited as directed by the Hon'ble High Court of Gujarat at Ahmedabad was convened and held on September 18, 2008. Mr. Mukesh M. Patel, Chairman appointed for the meeting conducted the meeting as directed in the Minutes of Order of the Gujarat High Court dated August 13, 2008. The Composite Scheme was approved by the requisite majority of the Equity Shareholders and by unanimous consent of Unsecured Creditors present and voting either in person or by proxy or as authorized representatives. The said Composite Scheme shall now be presented for approval and consideration of the Hon'ble High Court of Gujarat at Ahmedabad.4 Sep · Business
Press release dated September 04, 2008, titled "Zydus receives USFDA approval for Ramipril Cabsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Sep · Notice of Meeting
"The Hon'ble High Court of Gujarat, by an order made on August 13, 2008 has directed that a meeting of the Equity Shareholders and Unsecured Creditors of the Company be convened and held on September 18, 2008 for the pupose of considering, and if thought fit, approving with or without modification(s), the Composite Scheme of Arrangement between Carnation Nutra - Analogue Foods Limited and Cadila Healthcare Limited and Zydus Hospitals and Medical Research Private Limited and their respective equity shareholders and creditors." A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
21 Aug · Business
Further to the No-objection letter obtained from the stock exchanges, Cadila Healthcare Limited ('the Company') had filed a company application with the Hon'ble High Court of Gujarat on August 11,2008 for Composite Scheme of Arrangement between Carnation Nutra - Analogue Foods Limited and Cadila Healthcare Limited and Zydus Hospitals and Medical Research Private Limited and their respective equity shareholders and creditors.Subsequently, the Hon'ble High Court of Gujarat, by an order made on August 13, 2008 has directed that a meeting of the Equity Shareholders and Unsecured Creditors of the Company be convened and held on September 18, 2008 for the purpose of considering, and if thought fit, approving with or without modification(s), the Composite Scheme of Arrangement between Carnation Nutra - Analogue Foods Limited and Cadila Healthcare Limited and Zydus Hospitals and Medical Research Private Limited and their respective equity shareholders and creditors.12 Aug · Business
Press release dated August 12, 2008, titled "Zydus and WHO to develop next-generation biologicals to fight rabies". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Aug · Meeting
Copy of the Proceedings of the Annual General Meeting of the shareholders of the Company held on July 29, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Aug · Business
Press release dated August 01, 2008, titled "Zydus receives approval for Bromocriptine Mesylate Capsules. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
29 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 42913 lacs for quarter ending on 30-JUN-2008 against Rs. 45230 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 5564 lacs for the quarter ending on 30-JUN-2008 against Rs. 6640 lacs for the quarter ending on 30-JUN-2007.29 Jul · Business
Press release dated July 29, 2008, titled "Zydus Cadila Q1 Net profit up by 21%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 68571 lacs for quarter ending on 30-JUN-2008 against Rs. 57220 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 8968 lacs for the quarter ending on 30-JUN-2008 against Rs. 7390 lacs for the quarter ending on 30-JUN-2007.18 Jul · Board meeting
To consider amongst other unaudited financial results for the quarter ended on June 30, 2008.4 Jul · Business
Board of Directors of the Company at its meeting held on July 04, 2008 has approved the modalities of the restructuring of its Consumer Products Division ("CPD') for the benefit of its shareholders. The Board has approved a Composite Scheme of Arrangement for demerger of the CPD of the Company into Carnation, which is a 61.56% listed subsidiary Company of the Company and merger of Zydus Hospitals and Medical Research Private Limited ("Zydus Hospitals") into the Company and the share entitlement / exchange ratios. This Scheme will be, subject to requisite consent, approval of the shareholders of all three Companies, the Hon'ble High Court of Gujarat, respective Stock Exchanges and other regulatory authorities. Further the Company has submitted a copy of press release dated July 04, 2008, titled "Cadila Healthcare to restructure its consumer business and create a single listed entity. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Jul · Board meeting
To approve the "Composite Scheme of Arrangement between Cadila, Carnation and Zydus Hospitals and Medical Research Private Limited" to effect restructuring of the Consumer Products Division of Cadila and Carnation and also to realign the holding structure of the Company into Carnation based on the recommendations of consultants and to approve share swap ratios, under the Scheme, after considering the reports of the valuers.
Jun 2008
27 Jun · Results
With regards to passing of resolution through Postal Ballot in accordance with the provisions of Section 192A of the Companies Act, 1956 read with Companies (Passing of Resolution by Postal Ballot) Rules, 2001 for seeking approval of the members of the Company under Section 293(1)(a) and other applicable provisions, if any, of the Companies Act, 1956, to mortgage and / or create charge on all or any one or more of the movable / immovable properties or such other assets of the Company in favour of the lenders, we are pleased to inform you that the members of the Company have by overwhelming majority approved, through postal ballot process, the aforesaid resolution, the results of which was announced today i.e. 27th June 2008 by the Chairman which is as under: (1) Number of valid postal forms received : 2163. (2) Votes in favour of Resolution : 91367718 shares. (3) Votes against the Resolution : 13831 shares. (4) Number of invalid postal ballot forms received : 6. The vote cast "FOR" the above Ordinary Resolution out of the total votes polled are 99.98%. Therefore the Ordinary Resolution as mentioned in the Notice of Postal Ballot dated 29th April 2008 has been passed with requisite majority20 Jun · Disclosure
They propose to acquire 90,000,000 shares aggregating to 71.648% of the shares/voting rights of Cadila Healthcare Limited from Zydus Family Trust which holds 72% stake in Cadila Healthcare Limited. The mode of proposed acquisition is by way of inter-se-transfer and the date of proposed acquisition is June 27, 2008. The proposed acquisition price per share is Rs.2.077 per share at cost. The shareholding of Zydus Hospitals And Medical Research Private Limited after the proposed acquisition would be 90,000,000 shares aggregating to 71.648% of the shares/voting rights of Cadila Healthcare Limited.19 Jun · Updates
Board of Directors of the Cadila Healthcare Limited ("Cadila") at its Meeting held on June 17, 2008, has taken in-principle decision to transfer Cadila's Consumer Products Division ("CPD") into Carnation Nutra- Analogue Foods Limited ("Carnation"), 61.56% subsidiary of the Cadila. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jun · Board meeting
Outcome of the Meeting of Board of Directors of the Company held on June 17, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jun · Business
Press release dated June 16, 2008, titled "Zydus scores with first day launch of Venlafaxine Hydrochloride in the US".A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Jun · Board meeting
To consider options to consolidate / restructure the Consumer Product business of the group, including its listed subsidiary, namely Carnation Nutra-Analogue Foods Limited.